3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
41
Observational
6
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Interventions
3-Iodobenzylguanidine
6
Magnetic Resonance Spectroscopy
5
Amifampridine
5
gallium 68 PSMA-11
4
fludarabine phosphate
3
Cyclophosphamide
3
pembrolizumab
2
fluorodopa F 18
2
fludarabine
2
carbon-11 acetate
2
Whole-Body Irradiation
2
Oxaliplatin
2
Ga(III)-DOTATOC
2
Fluorouracil
2
Bortezomib
2
Bone Marrow Transplantation
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
venetoclax
1
veliparib
1
ulocuplumab
1
trametinib
1
selinexor
1
ponatinib
1
pegfilgrastim
1
omburtamab I-131
1
nirogacestat
1
neratinib
1
navitoclax
1
motexafin gadolinium
1
mifamurtide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Expanded_access
×
ponatinib
×
Clear all
NCT01549548
2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available